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Since the introduction of penicillin in
the 1940s, antimicrobial resistance (AMR)
has become an ever-increasing threat to
human and animal health (Carlet et al.,
2012; ITFAR, 2012). The low-dose antimi-
crobial use in food-producing animals for
production purposes, i.e., disease preven-
tion and growth promotion, has been
documented to drive AMR, though the
risk to human health from such uses
has been a source of a heated debate
among stakeholders including industry
members, citizen advocacy groups, aca-
demics, and public health workers (Davis
and Rutkow, 2012). In the United States
(US), it remains common practice to use
medically-important antibiotics1 for pro-
duction purposes. Since the 2000s, the
European Union (EU) has banned many
low-dose antimicrobial uses. The crucial
element to the debate has been whether
scientific evidence supports similar action
in the US. Industrial food animal pro-
duction advocates, henceforth “industry,”
claims that scientific evidence is currently
lacking, while other stakeholders argue
that a convincing and substantial body of
evidence exists to support policy change.
The US and the EU have taken vastly
different approaches to AMR surveillance
and research, and these choices have led
to a wide variance in the current policy
climate regarding antimicrobial use and
AMR.We argue that the EU has prioritized
1Based on definitions for critically-important
antimicrobials used by the Food and Agriculture
Organization of the United Nations, World Health
Organization, and World Organization for Animal
Health (OIE), and definitions of medically-important
antibiotics in the Preservation of Antibiotics for
Medical Treatment Act, first introduced to the U.S.
Congress in 1999.
scientific research and surveillance efforts
that target uses of antimicrobials in ani-
mals. The US has not invested deeply
in either research funding or surveillance
programs that include such uses. If pol-
icy shifts will occur in the US, changes in
AMR surveillance and allocation of scien-
tific research funding are required.
CURRENT US PRACTICES
The US National Antimicrobial Resistance
Monitoring System (NARMS) is a
joint effort of the US Department of
Agriculture (USDA), the Food and Drug
Administration (FDA), and the Centers for
Disease Control and Prevention (CDC)
for AMR surveillance. The three arms
of NARMS—VetNet (USDA), PulseNet
(CDC), and retail (FDA)—collect sam-
ples from animal carcasses at the time
of slaughter, human food-borne infec-
tions, and retail meat samples, respectively.
Techniques in each arm vary in regards
to both isolates collected and laboratory
definitions for resistance, making data
comparison across branches challenging
(US GAO, 2011). Collection of data on
antimicrobial use and sales in food animals
in the US is limited, though the FDA has
made recent efforts to obtain more data.
The Government Accountability Office, in
a report published in 2011, commented on
the limited scope of sampling techniques
in the US:
This non-random sampling method
means the NARMS data obtained . . . are
not representative of food animals across
the country and cannot be used for
trend analysis because bacteria tested
by NARMS are now collected at greater
rates from slaughter plants that are not
in compliance with food safety stan-
dards. According to FDA officials, due to
this sampling method, the resulting data
are skewed for NARMS purposes (US
GAO, 2011).
The lack of harmonization within NARMS
limits the interpretation of these data, with
resulting impacts on evidence available to
support science-driven policy.
Current NARMS funding is approx-
imately $7.8 million, bringing the per-
capita investment in this surveillance tool
to $0.025 (US GAO, 2011). Lack of fund-
ing is routinely cited as the primary cause
of limited government-led research and
lack of advancement in surveillance tech-
niques, though the lack of coordination
within the current approach suggests that
changes could be made to use existing
budget funds more effectively (Pew Trust,
2008; US GAO, 2011; IDSA, 2012).
CURRENT EUROPEAN PRACTICES
The European approach to AMR surveil-
lance, research, and policy development
began with individual country efforts,
with Denmark and Sweden as leaders. In
recent years, the EU has begun to compile
data from numerous countries through
the functions of the European Centers for
Disease Control, European Antimicrobial
Susceptibility Surveillance in Animals
Center, and the European Animal Health
Study. In general, European efforts have
been more systematic than US efforts,
including sampling of healthy and dis-
eased animals and people, monitoring
antimicrobial usage patterns through
novel techniques such as geomapping,
and using veterinarians to obtain samples
from awide variety of regions and animals,
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including pets (DANMAP, 2011; Davis
and Rutkow, 2012; IDSA, 2012; ITFAR,
2012; de Jong et al., 2013).
Selective bans on antimicrobials for
growth promotion were instituted in
the 1990s, and a complete ban of drugs
for non-therapeutic uses was established
in Denmark and the EU in 2000 and
2006, respectively (DANMAP, 2011;
US GAO, 2011). Research is priori-
tized and is typically led by industry
rather than government; this approach
may reflect differences in cultural or
social norms between the EU and US.
Indeed, industry participation in such
programs has been largely voluntary,
and the additional cost is thus often
internalized to industry rather than exter-
nalized to the public through government
expenditures.
COMPARISON OF APPROACHES
According to the 2011 GAO audit of
NARMS, policy in the EU, “. . . has been
built around the precautionary principle,
which states that where there are threats
of serious or irreversible damage, lack of
scientific certainty should not postpone
cost-effective measures to reduce risks to
humans” (US GAO, 2011). In contrast to
the US approach of risk assessment, the
EU method is buoyed by consumer con-
cern and voluntary industry measures. At
a recent meeting, the Infectious Disease
Society of America (IDSA) released a
statement comparing current US and EU
efforts:
Even given the value [National Health
Safety Network], [Emerging Infections
Program], Prevention Epi-centers,
NARMS, and [Multidrug Resistant
Repository and Surveillance Network]
provide, IDSA remains deeply con-
cerned about the lack of detailed,
publicly available data on both resis-
tance trends and human antimicrobial
use in humans, food animals and other
areas of agriculture and food produc-
tion in the United States. The U.S. is
far behind other countries in collecting
and benefiting from data on antibi-
otic consumption and resistance (IDSA,
2012).
In the same vein, the 2011 GAO report
noted that CDC did not routinely pub-
lish data on AMR patterns in pathogens
associated with outbreaks of foodborne ill-
ness (US GAO, 2011). Such statements
indicate the low political priority assigned
to AMR surveillance and program evalu-
ation in the US. Evaluation is a vital part
of any system, and as the 2011 GAO report
indicated, NARMS, FDA, USDA, and CDC
have conducted few evaluations. Without
regular evaluation, programs and policies
that are neither cost-effective nor impact-
ful can waste money and prevent new and
more efficacious systems from being put in
place.
DANMAP was established in 1995
with 2.4 million kroner ($0.3 million)
and in 2000 further supported with 2.6
million kroner resulting in a total of
5 million kroner ($0.7 million) of ini-
tial investment across that time period2.
This program was one of the pioneers
in European surveillance efforts, predat-
ing EU-wide efforts (Davis and Rutkow,
2012). Currently, DANMAP is not funded
by earmarked money but is a part of the
general tasks of Statens Serum Institut and
Danish Technological University (DTU-
Food) financed by Danish Ministry of
Health and the Danish Ministry of Food,
Agriculture, and Fisheries. Although the
budget for DANMAP changes relative to
general fund availability and is subject
to annual decreases, the budget from
the Ministry of Food, Agriculture and
Fisheries alone for all food research (not
just application to AMR) was 246 million
kroner ($44.8 million), or a per-capita
investment of $8 for 20143. Funding across
multiple federal agencies places US food
research investment at an estimated $1863
million, or a per-capita investment of less
than $6 for 20134. Given similar per-capita
budgets, the food safety and DANMAP
programs have more effectively influenced
AMR policy in Denmark than parallel
2Based on a year 2000 exchange rate of 7.3855kr/US
dollar. With a year 2000 Danish population of 4.8 mil-
lion, the per-capita investment was roughly $0.14. We
thank Robert Skov for his assistance in obtaining this
DANMAP funding information.
3Based on a December 1, 2013 exchange rate of
5.489810kr/US dollar. With a year 2013 Danish pop-
ulation of 5.6 million, the per-capita investment was
$8.
4Based on the sum of food safety budget estimates
of $42 million (NIFA), $108 million (ARS), $1 mil-
lion (ERS), $1425 (FDA), and $287 (NIH), for a total
of $1863 million (Ohlhorst et al., 2013). With a year
2013 US population of 320.6 million, the per-capita
investment was $5.8.
programs have in the US. This example
suggests that the choice of where and how
to apply funding may be more important
than total expenditure in the generation of
scientific evidence to support policy deci-
sions.
The role of industry in the US is com-
plex, and the 2008 report of the Pew
Commission on Industrial Farm Animal
Production noted, “We found significant
influence by the industry at every turn:
in academic research, agriculture policy
development, government regulation, and
enforcement” (Pew Trust, 2008). Industry
itself is not held accountable for ensuring
public health, nor is it charged with con-
tributing peer-reviewed research to sup-
port or refute its current or preferred
practices, yet it remains able to exercise
tremendous influence in government and
academia, especially among land grant
universities where industry funding has
largely replaced public research funding
(Pew Trust, 2008).
Hence, policy success, defined as both
action by agencies and reductions in AMR
rates, in the EU has been driven in part
by strategic allocation of funding sup-
port, adherence to the precautionary prin-
ciple, involvement of industry, and peri-
odic mandatory participation of EUmem-
bers in region-wide data collection efforts
(DANMAP, 2011; IDSA, 2012; Silley et al.,
2012). In contrast the US has not seen the
same returns relative to funding efforts,
has not applied the precautionary princi-
ple in formulating policy, has not required
participation of producers or benefited
from voluntary support by industry, and
has conducted limited and flawed surveil-
lance for antimicrobial use in livestock
and AMR.
RECOMMENDATIONS
In an era of resource constraints for gov-
ernment agencies, we do not expect AMR
surveillance efforts in the US to experi-
ence significant budget increases. The EU
approach, including the specific example
of Denmark, offers lessons for change in
the US. We propose that efforts be made
to provide minimal increases in funding
to obtain more representative and compa-
rable data, and to analyze data currently
being collected in a more effective way. For
example, NARMS data in the US are avail-
able online, but manipulation of the data
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is not feasible (Silley et al., 2012). Allowing
independent researchers and their stu-
dents to use the NARMS data for analysis
may lead to more rapid reports that can
be used for comparison with data from
other countries, while supplying a no-cost
source of analysis and enhancing educa-
tional opportunities. In particular, provi-
sion of data at the sample level, allowing
for analysis of cross-resistance patterns,
would inform both scientific and policy
efforts to understand and combat the rise
of AMR pathogens.
Additionally, a shift in industry’s role
toward a more harmonized partnership
with government and other stakeholders
would assist national efforts to address
the problem of AMR. Voluntary FDA
guidance to phase-in veterinary over-
sight and phase-out growth promotion
uses of antimicrobials in livestock is
a first step toward this goal (FDA,
2013). Following the EU example for
industry involvement in research efforts
would ultimately offer a solution to
meet the needs for representative sam-
pling within a country as large and
diverse as the US. While industry may
be faced with higher costs, all stake-
holders would benefit from improve-
ments in data collection—and hence data
interpretation—in driving evidence-based
policy change.
Ultimately, changes need to occur
within the US to encourage industry
accountability, research efforts, and gov-
ernment investment in adequate surveil-
lance systems. Some improvements within
the US surveillance system, such as report-
ing of data already collected, would require
minimal funding adjustments. AMR is a
pressing problem that threatens the health
and well-being of humans and animals,
with impacts through the food system.
Fundamental shifts in the governmental
and industry approaches, including struc-
tural changes to enhance data collection
and dissemination, are urgently needed to
generate science-based policies and then
understand the impact of the policies on
AMR.
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